BiotechTube
Perception Neuroscience

Perception Neuroscience

New York, United States· Est.
perceptionns.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $8M

Overview

Perception Neuroscience, founded in 2018 and based in New York, is advancing PCN-101 (R-ketamine), a glutamatergic modulator, for treatment-resistant depression. The company's strategy is based on nonclinical data suggesting R-ketamine may offer rapid antidepressant effects with fewer dissociative side effects and lower abuse potential than S-ketamine (Spravato®). It has completed Phase 1 studies, initiated a Phase 2a proof-of-concept trial, and secured a key partnership with Otsuka Pharmaceuticals for development in Japan. Perception operates as a private, pre-revenue entity with a lean operational team and a distinguished scientific advisory board.

PsychiatryNeuroscience

Technology Platform

Development of single-isomer (enantiomer) therapeutics targeting the NMDA receptor, specifically focusing on R-ketamine (arketamine) to dissociate rapid antidepressant efficacy from dissociative and abuse-related side effects.

Funding History

1
Total raised:$8M
Series A$8M

Opportunities

PCN-101 addresses a large, underserved market in treatment-resistant depression with a potential best-in-class profile, offering rapid efficacy with fewer side effects than the approved esketamine.
A successful profile could enable less restrictive administration, broadening patient access.
The partnership with Otsuka provides validation and a path to the key Japanese market.

Risk Factors

The company faces high clinical risk that Phase 2 data may not confirm the promising preclinical differentiation of R-ketamine.
It operates in a highly competitive and rapidly evolving landscape for rapid-acting antidepressants.
As a private, single-asset company, it is also vulnerable to financing risks for advancing into late-stage trials.

Competitive Landscape

Perception competes directly with Johnson & Johnson's Spravato® (esketamine), the approved market leader, and numerous clinics offering off-label racemic ketamine. The competitive set also includes other clinical-stage companies developing novel psychedelic (e.g., psilocybin) and non-psychedelic glutamatergic therapies, all aiming for rapid efficacy with improved tolerability.

More companies in Neuroscience & CNS →More companies in United States →